Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hahn, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hahn, A. F.
NEUROLOGY 1998;51:S16-S21
© 1998 American Academy of Neurology

Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with Intravenous Immunoglobulin

Angelika F. Hahn, MD, FRCP(C)

From the Department of Clinical Neurological Sciences, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada.

Address correspondence and reprint requests to Dr. A. F. Hahn, Department of Clinical Neurological Sciences, London Health Sciences Centre, University Campus, 339 Windermere Road, London, Ontario, Canada N6A 5A5.

Abstract.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a defined clinical entity with a chronic progressive or chronic relapsing course, lasting months to years. It causes variable but often severe chronic disability. CIDP is considered an autoimmune disorder caused by both cellular and humoral immune processes. Various immunomodulatory therapies, i.e., IVIg, therapeutic plasma exchange (PE), and prednisone, are of proven benefit. Comparative studies indicate that IVIg and PE confer equal short-term benefit. Efficacy of IVIg is maintained; regularly timed pulse treatments may stabilize relapsing CIDP. The combination of IVIg and prednisone may be advantageous in long-term management. Despite the high cost, IVIg is considered the preferred first treatment. The safety profile is similar to that reported for other conditions; close monitoring during the infusion is recommended. The precise mechanisms of IVIg action in CIDP are not known. Anti-idiotypic neutralization of autoantibodies, binding of complement, and blockade of macrophages may prevent the ongoing inflammatory demyelination.




This article has been cited by other articles:


Home page
 NeurologyHome page
M. Iijima, M. Tomita, S. Morozumi, Y. Kawagashira, T. Nakamura, H. Koike, M. Katsuno, N. Hattori, F. Tanaka, M. Yamamoto, et al.
Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP
Neurology, October 27, 2009; 73(17): 1348 - 1352.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. H. Ropper
Current treatments for CIDP
Neurology, April 22, 2003; 60(90083): S16 - 22.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
Z. Illes, T. Kondo, J. Newcombe, N. Oka, T. Tabira, and T. Yamamura
Differential Expression of NK T Cell V{alpha}24J{alpha}Q Invariant TCR Chain in the Lesions of Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy
J. Immunol., April 15, 2000; 164(8): 4375 - 4381.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
T. Kuntzer, A. J. Radziwill, R. Lettry-Trouillat, C. Naegeli, F. Ochsner, B. Erne, A. J. Steck, and J. Bogousslavsky
Interferon-{beta}1a in chronic inflammatory demyelinating polyneuropathy
Neurology, October 1, 1999; 53(6): 1364 - 1364.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.